Cytokine blocking strategy (blockade of IL-1 and IL-6) was the most often chosen treatment option for patients with clinically severe COVID-19 reaching support of 83.6% and 85.5% respondents, respectively, for use in stage III. This evidence concerns the gene IL6 and COVID-19.